2021
DOI: 10.7759/cureus.18356
|View full text |Cite
|
Sign up to set email alerts
|

Biochemical Risk Factors Associated With Hyperkalemia in Cirrhotic Patients

Abstract: Introduction: Patients with cirrhosis suffer from fluid and electrolyte imbalance. The usually reported electrolyte disorders include hyperkalemia, hyponatremia, and hypokalemia. The regional data about the prevalence and risk factors associated with hyperkalemia in cirrhotic patients are not sufficient enough. The purpose of this study is to determine various risk factors associated with hyperkalemia, which will assist in the early detection of cirrhotic patients at risk of hyperkalemia. Methods: This cross-s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 16 publications
0
1
0
Order By: Relevance
“…In patients with acute-on-chronic liver disease, hyperkalemia often develops secondary to reduced kidney function, resulting in impaired urinary K + excretion and increased renal sodium and water absorption [3,7]. Hyperkalemia may also be caused by the use of K + -sparing diuretics, such as spironolactone or eplerenone [10], which are recommended as first-line treatment in patients with cirrhosis and grade 2 ascites, either alone or in conjunction with a loop diuretic [11]. However, in this analysis, patients with chronic liver disease were at increased risk of hyperkalemia recurrence regardless of concomitant K + -sparing diuretic use.…”
Section: Discussionmentioning
confidence: 99%
“…In patients with acute-on-chronic liver disease, hyperkalemia often develops secondary to reduced kidney function, resulting in impaired urinary K + excretion and increased renal sodium and water absorption [3,7]. Hyperkalemia may also be caused by the use of K + -sparing diuretics, such as spironolactone or eplerenone [10], which are recommended as first-line treatment in patients with cirrhosis and grade 2 ascites, either alone or in conjunction with a loop diuretic [11]. However, in this analysis, patients with chronic liver disease were at increased risk of hyperkalemia recurrence regardless of concomitant K + -sparing diuretic use.…”
Section: Discussionmentioning
confidence: 99%